Table 3.
Prior studies in WHO grade III gliomas
| Design | Histology | N | Treatment | PFS (y) | OS (y) | Reference/Authors |
|---|---|---|---|---|---|---|
| Phase III | AG | 190 | RT + PCV |
– | 4.08 | Prados et al. (RTOG 9404) [13] |
| RT/BUdR +PCV | 4.50 | |||||
| Retrospective | AA | 109 | RT → PCV | 2.87 | NR | Brandes et al. [15] |
| RT → TMZ | 3.01 | NR | ||||
| Phase III | AA | 193 | RT | 1.03 | 1.99 | Hildebrand et al. (EORTC 26882) [16] |
| RT + DBD/BCNU | 1.23 | 2.28 | ||||
| Retrospective | AA, AOA | 60 | RT | 0.58 | 1.08 | Combs et al. [17] |
| RT/TMZ | 0.50 | 1.25 | ||||
| Phase III | AA, AO, AOA | 274 | RT | 2.55 | 6.01 | Wick et al. (NAO-04) [14] |
| PCV/TMZ | 2.66 | 6.88 | ||||
| Phase II | AA, AO | 33 | RT/TMZ → TMZ | 4.06 | 5.50 | Kim et al. [18] |
| Phase II | AA, AO, AOA | 32 | TMZ, 13-cRA | 3.15 | NR | Grauer et al. (RNOP-05) [12] |
| Retrospective | AA | 97 | RT/TMZ → TMZ | 3.0 | 4.2 | Minniti et al. [19] |
N number of patients; AG anaplastic glioma; AA anaplastic astrocytoma; AOA anaplastic oligoastrocytoma; AO anaplastic oligodendroglioma; RT radiation therapy; PCV procarbazine, lomustine, vincristine; BUdR bromodeoxyuridine; DBD dibromodulcitol; BCNU bichloroethylni-trosourea/carmustine; TMZ temozolomide; 13-cRA 13-cis-retinoic acid